News Article

Candesic provided commercial due diligence to the investors providing $80m of growth capital to pioneering AI drug discovery company CytoReason. CytoReason, which offers life sciences companies AI-enabled drug discovery tools to gather data-driven and molecular-level insights to improve success in clinical trials and optimize research and development, will use the funds to expand the use of its models for different indications, grow its molecular and clinical data and open an office in Cambridge, Massachusetts, later this year.

Read more about this investment below.

If you would like to know more about the services Candesic offers email [email protected] or contact us on +44 (0)20 70967680.